Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
June 25, 2021
RegMed Investors’ (RMi) closing bell: a good week even with Russell rebalances on a Friday
March 19, 2021
RegMed Investors’ (RMi) pre-open: welcome to Friday and a bounce back
March 18, 2021
RegMed Investors’ (RMi) pre-open: drops in futures scare me
November 3, 2020
RegMed Investors’ (RMi) pre-open: today’s outcome
November 2, 2020
RegMed Investors’ (RMi) pre-open: what’s motivating outcomes - speculation and shots in the dark
October 30, 2020
RegMed Investors’ (RMi) pre-open: hammer time, volatility rules as pre-election nerves and COVID infection rates set the “play”
June 30, 2020
RegMed Investors’ (RMi) closing bell: last trading day of month rallies solidifying the quarter
April 15, 2020
RegMed Investors’ (RMi) pre-open: what’s easing, certainly not economic indicators
April 14, 2020
RegMed Investors’ (RMi) closing bell: the velocity and strength of pricing needle moves dramatically due to capricious optimism
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors